Antiarrhythmic action of bethanidine.

Area of Science:

• Cardiology
• Electrophysiology
• Pharmacology

Background:

• Symptomatic ventricular tachycardia (VT) poses a significant clinical challenge.
• Limited therapeutic options exist for preventing VT induction.
• Bethanidine's efficacy in VT prevention requires further investigation.

Purpose of the Study:

• To compare the efficacy of bethanidine versus procainamide in preventing programmed electrical stimulation-induced VT.
• To evaluate the role of protriptyline in mitigating bethanidine's side effects.

Main Methods:

• 20 patients with symptomatic VT underwent electrophysiologic studies.
• Bethanidine (5-10 mg/kg) and procainamide (1000-1500 mg IV) were administered.
• Protriptyline (15 mg orally) was given pre-treatment to prevent orthostatic hypotension.

Main Results:

• Bethanidine protected 50% of patients not responsive to procainamide.
• Procainamide protected 8 of 16 patients.
• Long-term bethanidine therapy (11 months) showed no clinical VT recurrence; protriptyline attenuated hemodynamic changes.

Conclusions:

• Bethanidine is effective in preventing VT induction.
• Combined therapy with protriptyline improves tolerability by reducing orthostatic hypotension.
• Bethanidine may be a viable treatment option for VT beyond primary ventricular fibrillation.